ARROWHEAD PHARMACEUTICALS, INC.
ARWR evidence brief
What we can confirm
- BioSniper Score:
- 3.8 / 10
- Market Cap:
- $11.99B
- Lead Asset:
- Olpasiran (Phase 3)
What it means
What to watch
Prepared research question
What matters most for ARWR—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ARWR
Arrowhead Pharmaceuticals is a clinical-stage biotech company developing RNA interference (RNAi) therapeutics, with its lead candidate plozasiran in Phase 3 for severe hypertriglyceridemia and a pipeline spanning cardiometabolic, obesity, and CNS disorders.
Key risk: Operating losses persist
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 57 clinical trials · 1 catalyst for ARROWHEAD PHARMACEUTICALS, INC..
Arrowhead Pharmaceuticals is a clinical-stage biotech company developing RNA interference (RNAi) therapeutics, with its lead candidate plozasiran in Phase 3 for severe hypertriglyceridemia and a pipeline spanning cardiometabolic, obesity, and CNS disorders.
- Total revenue of $75.3M and net income of -$194.3M as of 2026-06-30 [sec].
- Shareholders' equity of $465.5M as of 2026-06-30 [sec].
- Plozasiran granted entry into the FDA STAR pilot program for severe hypertriglyceridemia (sHTG) as of 2026-10-07 [news].
- Phase 3 SHASTA-3 and SHASTA-4 trials of plozasiran in sHTG hit all endpoints including a 100% reduction in acute pancreatitis in high-risk patients [news].
- Pipeline includes olpasiran (Phase 3, partnered with Amgen) for atherosclerotic cardiovascular disease with elevated lipoprotein(a) [pipeline].
What works
- Plozasiran demonstrated strong efficacy in Phase 3 trials, with 79–81% triglyceride reduction in sHTG and a 100% reduction in acute pancreatitis in high-risk patients [news].
- The company has a deep RNAi pipeline with multiple candidates in Phase 1/2a or Phase 3, including ARO-INHBE for obesity/MASH and olpasiran partnered with Amgen [news][pipeline].
- FDA granted plozasiran entry into the STAR pilot program, which may accelerate review of its upcoming sNDA for sHTG [news].
What to weigh
- The company reported a net loss of $194.3M for the period ending 2026-06-30, indicating ongoing operating losses [sec].
- Plozasiran faces a competitive landscape with 63 competitors in hypertriglyceridemia, including AstraZeneca and Jiangsu HengRui Medicine [pipeline].
- The company's cash position and runway are not disclosed in the provided chunks, raising uncertainty about financial sustainability given the net loss [sec].
From the filings
Quoted directly from source documents.
Plozasiran achieved 79-81% TG reduction in sHTG trial
“Arrowhead's plozasiran shows 79-81% TG reduction in sHTG trial”
News · October 2, 2026
FDA granted plozasiran entry into the STAR pilot program
“the United States Food and Drug Administration (FDA) has granted plozasiran entry in the Split Real Time Application Review (STAR) pilot program”
News · October 7, 2026
Phase 3 SHASTA-3 and SHASTA-4 hit all endpoints including 100% reduction in acute pancreatitis
“SHASTA-3 and SHASTA-4 Hit on All Endpoints Including 100% Reduction in Acute Pancreatitis in High-Risk Patients”
News · July 22, 2026
Olpasiran is in Phase 3 for atherosclerotic cardiovascular disease with elevated lipoprotein(a)
“Olpasiran Indication: Atherosclerotic cardiovascular disease with elevated lipoprotein(a) Phase: Phase 3”
Catalyst timeline
- 2038-09-10 · Patent_Expiry · PLOZASIRAN SODIUM — Patent expiry for plozasiran sodium; may affect exclusivity and competitive landscape.
Risks & what to watch (3)›
Key risks
- Operating losses persist — Net loss of $194.3M as of 2026-06-30 [sec]
- Intense competition in sHTG — Plozasiran faces 63 competitors including AstraZeneca and Jiangsu HengRui [pipeline]
- Cash runway uncertainty — No cash position disclosed in provided chunks; net loss raises sustainability concerns [sec]
What to watch
- FDA review of plozasiran sNDA for sHTG under the STAR pilot program [news]
- Phase 3 data readouts for olpasiran (partnered with Amgen) in atherosclerotic cardiovascular disease [pipeline]
- Progress of ARO-INHBE in obesity/MASH from Phase 1/2a interim results [news]
- Patent expiry of PLOZASIRAN SODIUM on 2038-09-10 [catalyst]
Sources: News · Pipeline · Generated October 14, 2026 · How we verify sources →
Run ARROWHEAD PHARMACEUTICALS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ARROWHEAD PHARMACEUTICALS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
Cash runway data unavailable
D/E 3.54 · 0% dilution
Lead: Phase 3
1 candidate
1 upcoming, next in ~4349d
0 buys · 7 sells (180d)
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
432
Total value held
$7.44B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 18,161,519 | $1.14B |
| avoro capital advisors llc | 10,699,999 | $670.9M |
| fmr llc | 7,266,652 | $455.6M |
| vanguard portfolio management llc | 7,146,136 | $448.1M |
| state street corp | 6,496,130 | $407.3M |
| vanguard capital management llc | 6,032,416 | $378.2M |
| geode capital management, llc | 4,278,828 | $274.5M |
| fred alger management, llc | 3,342,493 | $209.6M |
| invesco ltd. | 3,280,647 | $205.7M |
| vestal point capital, lp | 2,275,000 | $142.6M |
Showing top 10 of 432 institutional holders of ARROWHEAD PHARMACEUTICALS, INC.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 12.8%
- Days to cover
- 7.3
- Shares short
- 12,939,446
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ARWR short interestGovernance
Frequently asked questions
What is the AI investment thesis for ARROWHEAD PHARMACEUTICALS, INC.?
Arrowhead Pharmaceuticals is a clinical-stage biotech company developing RNA interference (RNAi) therapeutics, with its lead candidate plozasiran in Phase 3 for severe hypertriglyceridemia and a pipeline spanning cardiometabolic, obesity, and CNS disorders.
What is ARROWHEAD PHARMACEUTICALS, INC.'s lead drug candidate?
ARROWHEAD PHARMACEUTICALS, INC.'s most advanced tracked candidate is Olpasiran (Phase 3) for Atherosclerotic cardiovascular disease with elevated lipoprotein(a).
What is ARROWHEAD PHARMACEUTICALS, INC.'s next catalyst?
ARROWHEAD PHARMACEUTICALS, INC.'s next tracked catalyst is a Patent_Expiry event — "Patent_Expiry: NDA219947" — expected September 10, 2038.
Who is the CEO of ARROWHEAD PHARMACEUTICALS, INC.?
Dr. Christopher R. Anzalone Ph.D. is the chief executive officer of ARROWHEAD PHARMACEUTICALS, INC. (ARWR).
Where is ARROWHEAD PHARMACEUTICALS, INC. headquartered?
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) is headquartered in Pasadena, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.